Results 171 to 180 of about 9,215 (199)

Strategies for enhancement of radioimmunotherapy

International Journal of Radiation Applications and Instrumentation. Part B. Nuclear Medicine and Biology, 1991
Two new strategies for increasing tumor uptake have been investigated. First the effect of interleukin-2 (IL-2) on tumor uptake of 125I-Lym-1 antibody in nude mice was investigated. Secondly, the use of 67Cu-labeled Lym-1 was evaluated in patients. In nude mice implanted with Raji human lymphoma, a greater than 2-fold enhancement of tumor uptake of ...
G, DeNardo, S, DeNardo, D, Kukis, H, Diril, C, Suey, C, Meares   +5 more
openaire   +2 more sources

Current status of radioimmunotherapy

Nuclear Medicine and Biology, 1994
Radioimmunotherapy with radiolabeled monoclonal antibodies is increasingly effective for hematopoietic tumors, with a number of investigators reporting persistent major responses. Radioimmunotherapy for solid tumors has been more difficult and only an occasional major response has been reported and these have so far not been persistent.
S M, Larson, C R, Divgi, A, Scott, G, Sgouros, M C, Graham, L, Kostakoglu, D, Scheinberg, N K, Cheung, J, Schlom, R D, Finn   +9 more
openaire   +2 more sources

Microdosimetric concepts in radioimmunotherapy

Medical Physics, 1993
In microdosimetry particular emphasis is placed on the stochastic fluctuation of dose in small target volumes such as individual cell nuclei or chromatin fiber, and their relevance to radiobiologic toxicity. Thus microdosimetry is intimately associated with models of radiation action.
J L, Humm, J C, Roeske, D R, Fisher, G T, Chen   +3 more
openaire   +2 more sources

Anti-HER2 Radioimmunotherapy

Breast Disease, 2000
HER2/neu is a receptor protein whose overexpression strongly correlates with poor prognosis in breast carcinomas. It is used increasingly as a therapeutic target for breast carcinomas in clinical human trials. In particular, monoclonal antibodies (mAbs) that target HER2/neu have been investigated for therapeutic applications.
M W, Brechbiel, T A, Waldmann
openaire   +2 more sources

Radioimmunotherapy of Ovarian Cancer

Hybridoma, 1995
Despite the advances in the management of ovarian cancer, the disease remains the leading cause of death from gynecological malignancies. As it generally remains confined to the peritoneal cavity, ovarian cancer is an attractive target for radioimmunotherapy via the intraperitoneal route of administration.
K N, Syrigos, A A, Epenetos
openaire   +2 more sources

Dosimetry models for radioimmunotherapy

Medical Physics, 1988
Tumor therapy using radiolabeled antibodies presents a challenging problem in absorbed dose determination. The purpose of this study is to evaluate the effect of tumor size on the absorbed dose distribution from beta‐emitters when the radiolabeled antibody is not uniformly distributed throughout the tumor.
V K, Langmuir, R M, Sutherland
openaire   +2 more sources

The radiation biology of radioimmunotherapy

Nuclear Medicine Communications, 2003
The treatment of cancer is a wide and varied field, encompassing many methods and modalities. Radioimmunotherapy is a technique which utilizes the ablative properties of radiation by delivering radioactive particles directly to the tumour cells. This paper presents a summary of the research evidence that relates to the optimization of the effect of ...
openaire   +2 more sources

Radioimmunotherapy in Brain Tumors

2012
Gliomas and meningiomas are the most frequent primary brain tumors. Surgery, external beam radiotherapy, and chemotherapy are, at present, the essential components in the therapeutic management of malignant brain masses. Nevertheless, these methods present limitations in terms of clinical response and rate of toxicity and morbidity. Because of the need
Grana, Chiara Maria, Paganelli, Giovanni
openaire   +2 more sources

Radioimmunotherapy for Waldenstrom's macroglobulinemia

Seminars in Oncology, 2003
Radioimmunotherapy targeting CD20 is a promising novel treatment for lymphoma. Prior trials have established the safe dose of Zevalin ((90)Y-ibritumomab tiuxetan; IDEC Pharmaceuticals) for patients with no more than 25% bone marrow (BM) involvement. Zevalin is expected to be an effective treatment for WM; however, the safe dose has not been defined.
openaire   +2 more sources

Future trends in radioimmunotherapy

Seminars in Oncology, 2005
Radioimmunotherapy (RIT) is currently approved in the United States only for use in low-grade follicular or transformed non-Hodgkin's lymphoma. One of the major issues in the construction of new clinical trials is deciding in which phase of disease RIT should be applied: upfront, as part of first-line treatment, in relapsed/refractory patients, in ...
openaire   +2 more sources